The latest Tweets from Hartaj Singh (@hartajsingh). “ Or the exquisite delicate thin curve of the new moon in spring; ” W. Whitman, Miracles. New York. Hartaj Singh works at Oppenheimer. Before joining Oppenheimer, he was the director/biotechnology analyst for BTIG and a portfolio manager for Tecumseh. Hartaj Singh is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Hartaj was Managing Director and Senior.
|Published (Last):||26 December 2007|
|PDF File Size:||20.21 Mb|
|ePub File Size:||8.22 Mb|
|Price:||Free* [*Free Regsitration Required]|
Hartaj Singh – Google Scholar Citations
Allison Rudary is a Director and Senior Analyst covering asset managers and business development companies. Metal Matrix omposites material. Rick received an international M. Journal hxrtaj Biological Chemistry 30, Ittai holds an M. Christopher Glynn Industrial Multi-Industry. Earlier, at Lehman Brothers, he was instrumental in the relaunch of the company’s mid- and large-cap coverage.
New sinyh related to this author’s research. He started his equity research career covering Israeli technology related equities for the firm. His coverage focuses on managed care, hospitals, nursing homes, home health, hospice, emergency services, and related healthcare services.
InJohn was named Head of Equity Research, a position he continues to hold today. Ian also spent some time on the buy side with Drake Capital Advisors.
Their combined citations are counted only for the first article. Articles 1—20 Show more.
Oppenheimer Analyst Bios
He initially focused on the emerging Israeli technology companies before broadening his coverage to Emerging Technology and Service companies. His research is focused on finding disruptive macro and micro software trends. Streetwise Reports is registered with the U.
Rupesh is quoted often in the financial press and serves frequently as a guest expert on various financial news channels. Glenn holds a B. Noah has been working with Colin since when he joined ThinkEquity. He has an M. The following articles are merged in Scholar.
The system can’t perform the operation now. He holds Finance and Communications degrees from Syracuse University. Ian Zaffino is Managing Director and is the Senior Analyst responsible for the coverage of event-driven special situations, including restructurings, post-bankruptcy equities and spinoffs. Prior to joining the firm, John was Senior Market Strategist at Ticonderoga Securities where he provided all macro, market outlook, and strategy ideas to the firm and its clients.
Brian is quoted often in the financial press and serves frequently as a quest expert on various financial news channels, such as CNBC and Bloomberg.
Over the next nine years, he led a team of four in covering over 45 stocks supporting both large cap institutional efforts and the firm’s small cap franchise. This “Cited by” count includes citations to the following articles in Scholar.
He also is a Chartered Financial Analyst and was a C. Esther has over 10 years of advisory experience in the life sciences sector including her time as an investment banker focused on Biotechnology transactions, and as a business strategy consultant to Major Pharmaceutical companies.
He served for three years in the Israeli Defense Forces as a senior investigator in the Military Police. While at ClinTrials Research, he coordinated clinical management for an anti-epileptic new drug application Sjnghand was the youngest clinical project manager to lead an NDA filing.
Dominick has been with the firm sinceoriginally working with Ben Chittenden covering Specialty Finance and Regional Banks.
Prior to Oppenheimer, Tim worked on the buy-side in an investment capacity at BlackRock. Prior to joining Oppenheimer, he was on the equity research team at Roth Capital Partners covering the eCommerce, Internet, and Media sectors.